Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6013078 | Epilepsy & Behavior | 2013 | 5 Pages |
Abstract
Developing new means of improving the effectiveness of existing antiepileptic drugs is a desirable way of tackling the dilemma of medically refractory epilepsy. Hypothetically, P-gp inhibitors (e.g., verapamil) might be used to counteract the removal of AEDs from the epileptogenic tissue. Such a strategy was adopted in this non-placebo-controlled, open-label, pilot study. We observed a significant achievement in seizure control associated with adjunctive use of verapamil in patients with refractory temporal lobe epilepsy.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Ali A. Asadi-Pooya, S. Mohammad Ali Razavizadegan, Alireza Abdi-Ardekani, Michael R. Sperling,